Statement regarding share price movement

October 15, 2014
Asahi Kasei Corp.

Asahi Kasei Corporation announced that a subsidiary of ZOLL Medical Corporation (ZOLL), a wholly owned US subsidiary of Asahi Kasei with operations in the field of critical care devices and systems, received a warning letter from the U.S. Food and Drug Administration (FDA) regarding LifeVest™ wearable defibrillator, dated September 23, 2014. Asahi Kasei considers that the fact and related media reports impacted on the Company’s share price and resulted in a decline in the Company’s share price on October 15, 2014.

ZOLL has already taken appropriate responses to the warning letter. Asahi Kasei, therefore, considers that this will not have a significant influence on ZOLL’s LifeVest™ business.


Adobe Readeris required to view these PDF files.

page top